^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CCNA2 expression

i
Other names: CCNA2, CCN1, CCNA, Cyclin A2
Entrez ID:
Related biomarkers:
3ms
Smoking-induced CCNA2 expression promotes lung adenocarcinoma tumorigenesis by boosting AT2/AT2-like cell differentiation. (PubMed, Cancer Lett)
Mechanistically, CCNA2 binding to CDK2 phosphorylates the AXIN1 complex, which in turn induces ubiquitination-dependent degradation of β-catenin and inhibits the WNT signaling pathway, thereby failing AT2 cell maintenance. These results uncover smoking-induced CCNA2 overexpression and subsequent WNT/β-catenin signaling inactivation as a hitherto uncharacterized mechanism controlling AT2 cell differentiation and LUAD tumorigenesis.
Journal
|
CCNA2 (Cyclin A2) • AXIN1 (Axin 1)
|
CCNA2 expression • CCNA2 overexpression
3ms
Clinicopathological role of Cyclin A2 in uterine corpus endometrial carcinoma: Integration of tissue microarrays and ScRNA-Seq. (PubMed, Int J Biol Markers)
CCNA2 was up-regulated and mainly located in T cells and B cells in UCEC. Overexpression of CCNA2 predicted unfavorable prognosis of UCEC.
Journal
|
CCNA2 (Cyclin A2) • FOXM1 (Forkhead Box M1) • E2F1 (E2F transcription factor 1)
|
CCNA2 expression • CCNA2 overexpression
5ms
Cancer-associated fibroblast-specific expression of the matricellular protein CCN1 coordinates neovascularization and stroma deposition in melanoma metastasis. (PubMed, Cancer Res Commun)
As drug resistance is linked to matrix deposition and neo-angiogenesis, these data suggest that CCN1, due to its multifaceted role, may represent a novel therapeutic target for drug-resistant melanoma. Our data further emphasize the essential role that cancer-associated, (universal) Col1A2-Cre-fibroblasts and extracellular matrix remodeling play in coordinating behavior among different cell types within the tumor microenvironment.
Journal • PD(L)-1 Biomarker • IO biomarker • Stroma
|
CCNA2 (Cyclin A2) • CCN1 (Cellular Communication Network Factor 1)
|
CCNA2 expression
6ms
Cyclin A2 expression as predictive biomarker in muscle-invasive upper tract urothelial carcinoma. (PubMed, Urol Int)
Low CCNA2 expression is significantly associated with worse OS. Thus, CCNA2 might serve as potential biomarker in muscle-invasive UTUC and may be used to characterize a subset of patients having an unfavorable outcome and for future risk-assessment scores.
Journal
|
TP53 (Tumor protein P53) • CCNA2 (Cyclin A2) • MKI67 (Marker of proliferation Ki-67)
|
TP53 expression • CCNA2 expression • CCNA2 overexpression
7ms
KLF14 activates the JNK-signaling pathway to induce S-phase arrest in cervical cancer cells. (PubMed, Front Immunol)
KLF14 also activated the JNK pathway to induce S-phase arrest and promote the expression of CDK2 and CCNA2. In summary, KLF14 activates the JNK-signaling pathway to induce S-phase arrest in cervical cancer cells.
Journal
|
CCNA2 (Cyclin A2) • CDK2 (Cyclin-dependent kinase 2) • KLF14 (KLF Transcription Factor 14) • MAPK8 (Mitogen-activated protein kinase 8)
|
KLF4 overexpression • CCNA2 expression • CDK2 expression
1year
Extraction, phytochemical characterization and anti-cancer mechanism of Haritaki churna: An ayurvedic formulation. (PubMed, PLoS One)
Halting of cells at S-phase causes induction of apoptosis in cancer cells. Cancer cells exhibiting DNA fragmentation, changes in expression of several apoptotic proteins such as Bcl2, cytochrome-c and formation of cleaved products of caspase 3 and PARP-1 suggests ellagic acid induces cell death via mitochondrial pathway of apoptosis.
Journal • PARP Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • CASP3 (Caspase 3) • CCNA2 (Cyclin A2)
|
CCNA2 expression
over1year
Geniposide inhibits cell proliferation and migration in human oral squamous carcinoma cells via AMPK and JNK signaling pathways. (PubMed, Exp Ther Med)
Mechanistically, geniposide activated the 5'-AMP-activated protein kinase signaling pathway and inhibited the JNK signaling pathway in SCC-9 cells (western blot analysis). The present results indicated that geniposide is able to inhibit the proliferation and migration of the tongue squamous carcinoma cell line SCC-9, suggesting a potential strategy for OSCC treatment.
Journal
|
CDH1 (Cadherin 1) • MMP2 (Matrix metallopeptidase 2) • CASP3 (Caspase 3) • CCNA2 (Cyclin A2) • CDK2 (Cyclin-dependent kinase 2) • BECN1 (Beclin 1)
|
CDH1 expression • CCNA2 expression
2years
Scutellarin alleviates lipopolysaccharide-induced renal injury via mediating cysteine-rich protein 61-connective tissue growth factor-nephroblastoma overexpressed gene 1 expression to inhibit nuclear factor-κB signaling pathway (PubMed, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue)
Scu could protect the renal function in SA-AKI mice, and the protective effect is associated with NF-κB signaling pathway and CCN1. Thus, Scu could alleviate LPS-induced kidney injury by regulating the NF-κB signaling pathway.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • CCL2 (Chemokine (C-C motif) ligand 2) • CCNA2 (Cyclin A2) • IL1B (Interleukin 1, beta) • CCN1 (Cellular Communication Network Factor 1) • CTGF (Connective tissue growth factor)
|
CCNA2 expression
2years
Identification of MBOAT2 as an Unfavorable Biomarker Correlated with KRAS Activation and Reduced CD8 T-Cell Infiltration in Pancreatic Cancer. (PubMed, J Oncol)
Lastly, MBOAT2 overexpression reduced the infiltration level of CD8 T-cells, plasmacytoid dendritic cells, and activated dendritic cells but triggered a high type-2 T helper/type-1 T helper cell ration (Th2/Th1 ration) in PC. Our findings suggest that MBOAT2 is a potential protooncogene in PDAC that predicts a poor prognosis and is related to KRAS activation and inferior infiltration of CD8 T-cells in PC.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • CD8 (cluster of differentiation 8) • CCNA2 (Cyclin A2) • CDK2 (Cyclin-dependent kinase 2)
|
KRAS mutation • CCNA2 expression • CDK2 expression
2years
Roles for CCN proteins in Lysophosphatidic Acid and Sphingosine 1-Phosphate Signaling in Prostate Cancer Cells. (PubMed, FASEB J)
The results of this study suggest that CCN proteins may play roles in LPA- and S1P-induced signaling in prostate cancer cells and are thus potential therapeutic targets.
Journal
|
FN1 (Fibronectin 1) • CCNA2 (Cyclin A2) • CCN1 (Cellular Communication Network Factor 1) • CTGF (Connective tissue growth factor)
|
CCNA2 expression
2years
The Predictive Competing Endogenous RNA Regulatory Networks and Potential Prognostic and Immunological Roles of Cyclin A2 in Pan-Cancer Analysis. (PubMed, Front Mol Biosci)
Furthermore, CCNA2 is positively associated with expressions of immune checkpoints (CD274, CTLA4, HAVCR2, LAG3, PDCD1, and TIGIT) in most cancer types. Our first CCNA2 pan-cancer study contributes to understanding the prognostic and immunological roles and potential upstream molecular mechanisms of CCNA2 in different cancers.
Journal • PD(L)-1 Biomarker • IO biomarker • Pan tumor
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule) • CD27 (CD27 Molecule) • CCNA2 (Cyclin A2) • MIR27B (MicroRNA 27b) • FGD5-AS1 (FGD5 Antisense RNA 1) • MIR204 (MicroRNA 204)
|
LAG3 expression • CCNA2 expression • CCNA2 overexpression
over2years
PKMYT1 regulates the proliferation and epithelial-mesenchymal transition of oral squamous cell carcinoma cells by targeting CCNA2. (PubMed, Oncol Lett)
In addition, PKMYT1 was demonstrated to bind to CCNA2, and knocking down PKMYT1 resulted in inhibitory effects on cell proliferation, colony formation ability, migration, invasion and EMT by downregulating CCNA2 expression. PKMYT1 was observed to regulate the proliferation, migration and EMT of OSCC cells by targeting CCNA2, which may be used in the future to improve OSCC treatment.
Journal
|
CCNA2 (Cyclin A2) • PKMYT1 (Protein Kinase Membrane Associated Tyrosine/Threonine 1)
|
CCNA2 expression
over2years
CDCA7 Facilitates Tumor Progression by Directly Regulating CCNA2 Expression in Esophageal Squamous Cell Carcinoma. (PubMed, Front Oncol)
Furthermore, CDCA7 was found to directly bind to CCNA2, thus promoting its expression. Our results reveal a novel mechanism of CDCA7 that it may act as an oncogene by directly upregulating CCNA2 to facilitate tumor progression in ESCC.
Journal
|
CCNA2 (Cyclin A2)
|
CCNA2 expression
almost3years
Long non-coding RNAs HERH-1 and HERH-4 facilitate cyclin A2 expression and accelerate cell cycle progression in advanced hepatocellular carcinoma. (PubMed, BMC Cancer)
The oncogenic lncRNA HERH-1/4 promoted CCNA2 expression at the transcriptional and post-transcriptional levels and accelerated cell cycle progression in HCC cells. The HERH-1-CREB1-CCNA2 and HERH-4-miR-29b/c-CCNA2 axes served as molecular stimuli for HCC advance.
Journal
|
CCNA2 (Cyclin A2) • CREB1 (CAMP Responsive Element Binding Protein 1)
|
CCNA2 expression
almost3years
TNF antagonizes CCN1 in apoptosis in esophageal adenocarcinoma. (PubMed, Cytokine)
Furthermore, we found that CCN1 boosted ADAM17-mediated cleavage of TNF receptors through ITGA11 and the soluble decoy receptors generated by this action neutralized TNF activity. Taken together, CCN1 and TNF antagonize each other in esophageal cancer cells.
Journal
|
CCNA2 (Cyclin A2) • ADAM17 (ADAM Metallopeptidase Domain 17)
|
CCNA2 expression
almost3years
E2F1 transcriptionally regulates CCNA2 expression to promote triple negative breast cancer tumorigenicity. (PubMed, Cancer Biomark)
Our data indicate that E2F1 promotes TNBC proliferation and invasion by upregulating CCNA2 expression. E2F1 and CCNA2 are potential candidates that may be targeted for effective TNBC treatment.
Journal
|
CCNA2 (Cyclin A2) • E2F1 (E2F transcription factor 1)
|
CCNA2 expression • CCNA2 overexpression
3years
Integrative analysis of key candidate genes and signaling pathways in ovarian cancer by bioinformatics. (PubMed, J Ovarian Res)
Taken together, our study provided evidence concerning the altered expression of genes in ovarian cancer tissues compared with normal tissues. In vivo and in vitro experiments are required to verify the results of the present study.
Journal
|
TOP2A (DNA topoisomerase 2-alpha) • CCNA2 (Cyclin A2) • CDC20 (Cell Division Cycle 20) • CDK1 (Cyclin-dependent kinase 1) • KIF11 (Kinesin Family Member 11) • BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B) • CCNB1 (Cyclin B1) • CDCA8 (Cell Division Cycle Associated 8)
|
CCNA2 expression • CCNA2 overexpression
3years
In silico analysis of differentially expressed genesets in metastatic breast cancer identifies potential prognostic biomarkers. (PubMed, World J Surg Oncol)
Transcriptome datasets of metastatic breast cancer obtained from Oncomine allow the identification of metastatic breast cancer-specific biological functions, pathways, and novel biomarkers to predict clinical outcomes of breast cancer patients. Further functional studies are needed to warrant validation of their roles as functional tumor-promoting or tumor-suppressing genes.
Journal
|
EGFR (Epidermal growth factor receptor) • CCNA2 (Cyclin A2) • LRIG1 (Leucine Rich Repeats And Immunoglobulin Like Domains 1)
|
CCNA2 expression • CCNA2 overexpression
over3years
Integrated Profiling Identifies CCNA2 as a Potential Biomarker of Immunotherapy in Breast Cancer. (PubMed, Onco Targets Ther)
Immunohistochemistry results showed that CCNA2 expression in carcinoma tissues was elevated compared with normal control. CCNA2 identified as a potential immune therapy marker in breast cancer, which were first reported here and deserved further research.
Journal • IO biomarker
|
CCNA2 (Cyclin A2)
|
CCNA2 expression
over3years
Association of a novel endometrial cancer biomarker panel with prognostic risk, platinum insensitivity, and targetable therapeutic options. (PubMed, PLoS One)
Integrating these molecular aberrations generated a molecular biomarker panel with significant prognostic discrimination (P = 5.8×10-7); adjusting for age, histology, grade, myometrial invasion, TP53 status, and stage, only CCNA2-H/E2F1-H (P = .0003), FBXW7-mu/PPP2R1A-mu (P = .0002), and stage (P = .017) were significant. The generated prognostic molecular classification system identifies dissimilar signaling aberrations potentially amenable to targetable therapeutic options.
Journal
|
TP53 (Tumor protein P53) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • CCNA2 (Cyclin A2) • FOXM1 (Forkhead Box M1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • E2F1 (E2F transcription factor 1)
|
TP53 mutation • FBXW7 mutation • CCNA2 expression
over3years
Cyclin A2 maintains colon homeostasis and is a prognostic factor in CRC. (PubMed, J Clin Invest)
A meta-analysis of 11 transcriptome datasets comprising 2,239 primary CRC tumors displayed different CCNA2 (the mRNA coding for cyclin A2) expression levels among the CRC tumor subtypes with highest in CMS1 and lowest in CMS4. Moreover, high expression of CCNA2 was found to be a new independent prognosis factor for CRC tumors.
Journal
|
CCNA2 (Cyclin A2)
|
CCNA2 expression
over3years
Expression patterns and prognostic values of the cyclin-dependent kinase 1 and cyclin A2 gene cluster in pancreatic adenocarcinoma. (PubMed, J Int Med Res)
The results of this study suggest that CDK1 and CCNA2 may be potential therapeutic targets and prognostic biomarkers in patients with PAAD.
Journal
|
CCNA2 (Cyclin A2) • CDK1 (Cyclin-dependent kinase 1)
|
CCNA2 expression
over3years
CSN1 facilitates proliferation and migration of hepatocellular carcinoma cells by upregulating cyclin A2 expression. (PubMed, Mol Med Rep)
Lastly, xenograft experiments indicated that CSN1 promoted HCC tumor growth in vivo. The present study suggested that CSN1 inhibition could represent a potential approach for the prevention of HCC progression and metastasis.
Journal
|
CCNA2 (Cyclin A2)
|
CCNA2 expression
almost4years
Neuropilin-1 is up-regulated by cancer-associated fibroblast-secreted IL-8 and associated with cell proliferation of gallbladder cancer. (PubMed, J Cell Mol Med)
Additionally, the IL-8 mediated MDM2 and CCNA2 expression were affected by NRP-1 knockdown. Our findings suggested that NRP-1 was up-regulated by CAF-secreted IL-8, which subsequently promoted GBC cell proliferation, and these molecules may serve as useful prognostic biomarkers and therapeutic targets for GBC.
Journal
|
CXCL8 (Chemokine (C-X-C motif) ligand 8) • CCNA2 (Cyclin A2) • NRP1 (Neuropilin 1)
|
CCNA2 expression • CXCL8 expression
almost4years
Ribosome Assembly Factor URB1 Contributes to Colorectal Cancer Proliferation via Transcriptional Activation of ATF4. (PubMed, Cancer Sci)
This study demonstrates that URB1 contributes to oncogenesis and CRC growth through XBP1-medaited transcriptional activation of ATF4. Therefore, URB1 may be a potential therapeutic target for CRC.
Journal
|
CCNA2 (Cyclin A2) • XBP1 (X-box-binding protein 1)
|
CCNA2 expression
almost4years
LukS-PV induces cell cycle arrest and apoptosis through p38/ERK MAPK signaling pathway in NSCLC cells. (PubMed, Biochem Biophys Res Commun)
Treatment of NSCLC with LukS-PV combined with p38 and ERK inhibitors reversed the pro-apoptotic and pro-cell cycle arrest effects of LukS-PV. Overall, these findings indicate that LukS-PV has anti-tumor effects in NSCLC and may contribute to the development of anti-cancer agents.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • CCNA2 (Cyclin A2) • CDK2 (Cyclin-dependent kinase 2)
|
CCND1 expression • CCNA2 expression • CDK2 expression
4years
Hsa_circ_0003732 promotes osteosarcoma cells proliferation via miR-545/CCNA2 axis. (PubMed, Biosci Rep)
In addition, hsa_circ_0003732 could elevate CCNA2 expression via miR-545, resulting in the promotion of OS cells proliferation. Altogether, our findings demonstrate that hsa_circ_0003732 promotes OS cells proliferation via miR-545/CCNA2 axis and imply hsa_circ_0003732 may be a potential prognosis biomarker and therapeutic target for OS.
Journal
|
CCNA2 (Cyclin A2)
|
CCNA2 expression